CAS: 5807-09-0; 4-Morpholinobutanoic Acid

相似化合物

173390-53-9 80667-39-6 39493-84-0

上下游产品

3-morpholin-4-ylpropionic acid ethyl ester methyl 4-morpholinobutanoate 4-morpholino-N-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenyl)butanamide N-[2-({2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}amino)-4-(2,4-dichlorophenyl)pyrimidin-5-yl]-4-morpholin-4-ylbutanamide

📜Methyl 4-Morpholinobutanoate置于水体系中,用 甲醇 作为反应溶剂,以0.22 G的收率获得产物4-吗啉-4-基丁酸盐酸盐
参考文献:Qsar和分子对接研究新型杂环gaba类似物对gaba-At的抑制活性.
标题:Qsar和分子对接研究新型杂环gaba类似物对gaba-At的抑制活性.
摘要:我们以前曾报道过作为荧光假单胞菌gaba-At酶抑制剂的新gaba类似物的合成,体外和计算机活性,其中γ-位的氮原子嵌入杂环支架中.为了找到更有效的抑制剂,我们现在报告合成一组新的gaba类似物,这些类似物在γ位具有更宽的杂环骨架,例如噻唑烷,甲基取代的哌啶,吗啉和硫代吗啉,并确定了它们的抑制潜力荧光假单胞菌的gaba-At酶.这些结构修饰导致化合物9B显示出对该酶的73%抑制.ptz诱导的雄性cd1小鼠癫痫发作的体内研究表明,化合物9B在0.50 Mmole / Kg剂量下具有神经保护作用.进行了qsar研究,以发现与gaba支架结构变化相关的分子描述符,以解释其对gaba-At的抑制活性.使用3D分子描述符使我们能够提出gaba类似物对映体活性形式.为了通过分子对接评估与荧光假单胞菌和人gaba-At的相互作用,进行了同源性模型的构建.通过这些计算,9B显示了与gaba-At两种酶的强
DOI:10.3390/molecules23112984

专利信息

专利号:US-4665074-A
优先权日:1984-05-10
标 题:6-(polyfluoroalkoxyphenyl) pyridazinones, their compositions, synthesis and use
发明人：AMSCHLER HERMANN
权利人:BYK GULDEN LOMBERG CHEM FAB
摘要:6-aryl-3[2H]pyridazinones of formula I (I) in which one of the substituents R1 and R2 denotes hydrogen or (C1-C4)-alkoxy, and the other denotes polyfluoro-(C1-C4)-alkoxy, and their pharmacologically-tolerated salts are suitable as bronchospasmolytic and cardiotonic active compounds. Processes for their preparation and appropriate medicaments are indicated.

专利号:US-5378690-A
优先权日:1986-12-19
标题 :New renin-inhibitory oligopeptides, their preparation and their use
发明人：MORISAWA YASUHIRO; KATAOKA MITSURU; YABE YUICHIRO; IIJIMA YASUTERU; TAKAHAGI HIDEKUNI; KOIKE HIROYUKI; KOKUBU TATSUO; HIWADA KUNIO
权利人:SANKYO CO
摘要:Oligopeptides of formula (I): (I) where R1-R5 are various organic groups, and A represents a group of formula -NH- or -(CH2)n-, in which n represents an integer of from 1 to 3, have renin-inhibitory activity and are particularly suitable for oral administration. They may be prepared by condensing their component amino acids or lower oligopeptides using conventional peptide synthesis reactions.